Close Menu

Drug companies are setting up R&D arms in China, staffing them with local scientists or expat-trained Chinese scientists, to encourage innovative drug research in the country. The GSK R&D center in Shanghai will have a first-year operating budget of $40 million, and AstraZeneca’s Innovation Center China was set up in June 2006 to develop drugs for gastric tract and liver cancers that are prevalent in China.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.